Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Diabetic vascular complications are leading causes of acquired blindness, end-stage renal failure, a variety of neuropathies, and accelerated atherosclerosis, which may be involved in the disabilities and high mortality rates suffered by diabetic patients. Continuous hyperglycemia is involved in the pathogenesis of diabetic micro- and macrovascular complications via various metabolic pathways, and numerous hyperglycemia-induced metabolic and hemodynamic conditions exist, including increased generation of various types of advanced glycation end-products (AGEs). Recently, we demonstrated that glyceraldehyde-derived AGEs (Glycer-AGEs), the predominant components of toxic AGEs (TAGE), play an important role in the pathogenesis of angiopathy in diabetic patients. Moreover, a growing body of evidence suggests that the interaction of TAGE with the receptor for AGEs (RAGE) alters intracellular signaling, gene expression, and the release of pro-inflammatory molecules and elicits oxidative stress generation in numerous types of cells, all of which may contribute to the pathological changes observed in diabetic vascular complications. Therefore, the inhibition of TAGE formation, blockade of TAGE-RAGE interaction, and the suppression of RAGE expression or its downstream pathways are promising targets for therapeutic interventions against diabetic vascular complications. In this review, we discuss the pathophysiological role of the TAGE-RAGE-oxidative stress system and related therapeutic interventions for preventing the development and progression of diabetic vascular complications. Keywords: Diabetic vascular complications, advanced glycation end-products (AGEs), toxic AGEs (TAGE), oxidative stress, soluble RAGE (sRAGE), renin-angiotensin system (RAS), pigment-epithelium-derived factor (PEDF), complications, glycation, AGEs, for AGEs, stress, RAGE, angiotensin, epithelium, (CVD), (DM), (DCCT-EDIC), (IMT), (UKPDS), (CML), (EC), (VEGF), (ICAM-1), GAPDHA, Fructose, (MCP-1), (TNF-α), IL-1β, (DECODE), (FPG), IMT, (PPG), CML, (ACEI), ICAM-1, MCP-1, VEGF, (NAC), (iNOS), NADPH, ROS, (CKD), DCCT, UKPDS, (CRF)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease
Yan, S. D., Chen, X., Fu, J., Chen, M., Zhu, H., Roher, A., Slattery, T., Zhao, L., Nagashima, M., Morser, J., et al. (1996) · Nature · doi:10.1038/382685a0 · Cited by 2,012 · cited 2×
“Several types of AGEs binding proteins and/or receptors for AGEs such as RAGE [32-36]; oligosaccharyl transferase-48 (AGE-R1) [37]; galectin-3 (AGE-R3) [38]; CD36 [39]; macrophage scavenger receptors types 1 and 2 (MSR-1 & -2) [40]; and fasciclin EGF-like, laminintype EGF-like, and link domain-containing scavenger rec…”
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 11×
“More recently, we investigated the effects of nateglinide, which has been shown to improve postprandial hyperglycemia, on HbA1c, Glc-AGE, and TAGE levels in GK rats [106].”
InfluentialGlucose Tolerance and Cardiovascular Mortality: Comparison of Fasting and 2-Hour Diagnostic Criteria
(2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.397 · Cited by 1,371 · cited 3×
“Acarbose did not affect other anthropometric or metabolic variables; i.e., there were no significant differences in body mass index, blood pressure, HbA1c, FPG, or lipid parameters between before and after treatment with acarbose.”
Hanefeld, M., Fischer, S., Julius, U., Schulze, J., Schwanebeck, U., Schmechel, H., Ziegelasch, H. J., & Lindner, J. (1996) · Diabetologia · doi:10.1007/s001250050617 · Cited by 873 · cited 2×
“There is a growing body of evidence to suggest that postprandial hyperglycemia plays an important role in the pathogenesis of CVD [104, 105].”
Ramasamy, R., Vannucci, S. J., Yan, S. S. D., Herold, K., Yan, S. F., & Schmidt, A. M. (2005) · Glycobiology · doi:10.1093/glycob/cwi053 · Cited by 834
Koschinsky, T., He, C.-J., Mitsuhashi, T., Bucala, R., Liu, C., Buenting, C., Heitmann, K., & Vlassara, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6474 · Cited by 792
YONEKURA, H., YAMAMOTO, Y., SAKURAI, S., PETROVA, R. G., ABEDIN, M. J., LI, H., YASUI, K., TAKEUCHI, M., MAKITA, Z., TAKASAWA, S., et al. (2003) · Biochemical Journal · doi:10.1042/bj20021371 · Cited by 716
Self-citation
Cited by
Vistoli, G., De Maddis, D., Cipak, A., Zarkovic, N., Carini, M., & Aldini, G. (2013) · Free Radical Research · doi:10.3109/10715762.2013.815348 · Cited by 823
Sandireddy, R., Yerra, V. G., Areti, A., Komirishetty, P., & Kumar, A. (2014) · International Journal of Endocrinology · doi:10.1155/2014/674987 · Cited by 364
Byun, K., Yoo, Y., Son, M., Lee, J., Jeong, G.-B., Park, Y. M., Salekdeh, G. H., & Lee, B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.030 · Cited by 357
“Bisphosphonateswere found to inhibit toxic AGEs-mediated inflammation and finally stopped ROS formation during the pathogeneses of the vascular complications of diabetes (Takeuchi et al., 2010).”
Acetaldehyde-Derived Advanced Glycation End-Products Promote Alcoholic Liver Disease
Hayashi, N., George, J., Takeuchi, M., Fukumura, A., Toshikuni, N., Arisawa, T., & Tsutsumi, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070034 · Cited by 41
Self-citation
Metadata
- Authors
- Takeuchi, M., Takino, J.-I., & Yamagishi, S.-I.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2010-11-01
- Volume
- 11
- Issue
- 11
- Pages
- 1468-1482
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2139372505
- Cited by
- 95
- References
- 19
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy. https://app.cochat.ai/papers/10.2174/1389450111009011468
- The paper
- Takeuchi, M., Takino, J.-I., & Yamagishi, S.-I. (2010). Involvement of the Toxic AGEs (TAGE)-RAGE System in the Pathogenesis of Diabetic Vascular Complications: A Novel Therapeutic Strategy. Current Drug Targets. https://doi.org/10.2174/1389450111009011468
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.